NY-BORN
21.4.2021 15:14:06 CEST | Business Wire | Press release
Total global e-commerce sales represent over $25 trillion in value today, with B2B e-commerce global merchandise value representing more than $12 trillion (Statista). With close to 2 billion websites online as of January 2021, the process of navigating products and determining quality sources can be an arduous, time-consuming, and sometimes impossible task. With billions of individual products and brands represented online and the number of products only increasing by the minute, the importance of curation becomes a critical expertise to support digital transactions. Layer in the changing ways consumers make purchase decisions, including assessing sustainability, integrity, and purpose, and the importance of product strategy is perhaps more vital than ever.
The product curation process creates bespoke collections that appeal to specific demographics and niche customer groups. Modern product curation leverages customer segmentation data and purchase behavior information, followed by personalization techniques to drive product engagement and understanding, create supplemental content around products and ultimately increase transaction value. Today, BORN and Alkeon announce industry veteran Stewart Mancey as Director of E-Concession & Retail Partners, joining a deep bench of global experts from multiple categories. As Director of E-Concession & Retail Partners, Stewart will work closely with Pierre Sapin (Chief Partnership Officer), Brendan Wypich (Chief Design & Product Officer), and Jean-Christophe Chopin (CEO and Founder of BORN and former ex-Verisign and *ETrade EU founder) . Mancey will work with brands and retailers on both Alkeon and BORN. His prestigious training at Harrods and knowledge of the creativity behind each retailer will lead BORN to curate purpose-led lifestyle brands using the filters of integrity, functionality, and desirability.
Stewart states, “Twenty years at Harrods has given me a wonderful experience, fabulous industry contacts, and a deep understanding of the power of curation across multiple categories. As Head of Curation for BORN and Alkeon, I’ll guide the product strategy for both, carefully curating across multiple dimensions that reflect today’s buying priorities and creating the ideal mix representing a cross-section of the best products and companies in the world. We want to take a load of sifting off of buyers and consumers and allow them to experience best-in-class product discovery powered by machine learning, delivered in a personalized experience and a beautiful environment that leverages the latest in technology.”
Stewart started his successful buying career at Harrods when he moved from the shop floor in 2003, working through the buying office in Women’s Superbrands before becoming Buyer of Eveningwear, Armani, and Ralph Lauren after three years. He eventually moved over to Menswear in 2007, where he was Senior Buyer for Men’s Superbrands & Tailoring, overseeing over £10m in renovations and delivering strong growth throughout his four years. In 2011, Stewart added the title of Head of Buying for Sports and managed the London Olympic strategy for Harrods, along with an additional £5m renovation. In 2013, Stewart took over Head of Buying for Furniture, Technology, and Toys and increased his remit in 2017 to include Homewares. After 21 incredibly successful years with Harrods, Stewart today joins BORN and its B2B extension Alkeon. Stewart will be a key player in the vital balance between designed technology and brand culture within both BORN and Alkeon’s market networks.
CEO Jean-Christophe Chopin states, “ Our ambition across BORN and Alkeon is to transform the B2B and B2C supply chains, reimagining discovery, transaction, and connection for both communities. Stewart adds critical and unique expertise to our executive leadership, which is a collection of the best minds in curation, commerce, community, and content. Stewart will contribute his years of knowledge of culture and brands, his deep understanding of the chains of commerce across multiple categories, his leading editorial expertise, and his unmatched Rolodex of brands and creators. We are delighted to have him.”
About BORN:
BORN is a holding company specializing in digital, data-led solutions to optimize retail and wholesale supply chains and reimagine discovery and transactions online. BORN owns Alkeon, a suite of B2B solutions and software products that facilitate digital transformation, as well as BORN.com, a platform that connects a global network of design-led brands and retailers. BORN has also curated and hosted the BORN Awards for 10 years in celebration of purpose led products and creativity. BORN is led by CEO Jean-Christophe Chopin, ex-founder of *ETrade EU and Verisign EU.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210421005162/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom